O uhaxi ua kijimbu mu mala (cancer de próstata) uene ua kaiadi ku mauhaxi ene mu jibha nau o mala ku mundu uoso, ku muvu ua 2018 kua moneka 1.276 dia mazunda a athu, o uhaxi iú ua tenesa 7.1% ia mala oso ene mu kata.
O uhaxi ua kijimbu mu manhinga a athu, u jibha ué athu avulu, ku muvu ua 2018 kuafu 37.005 ia athu ku mundu uoso.
Maji o uhaxi iú uene mu jibha dingi athu avulu, mu jixi ja África, o ixi ia Nigéria iene ia beta ku kala ni uhaxi iú.
Mu ixi ia Nigéria, o uhaxi ua kijimbu mu mala, uene ua beta o kota ku jibha o mala, o uhaxi iú uene mu jibha ué 32.8 dia mala, ni 16.3 dia mala mu 100.000 ia mala.
Kiki ki kyene mu bhita dingi mu jixi ja América do Norte.
O ku mona o uhaxi mu kithangana kia tokala, ni ku kamba o ji makina ja ku saka, ni ku kamba ku soneka o maka, ku bhangesa o athu ku fua mu ixi ia Nigéria.
Mu ixi ia Estados Unidos, o uhaxi ua kijimbu mu mala, uene ua kaiiadi mu jibha o mala, mu mivu ioso 40.000 ja mala ene mu fua.
O uhaxi iú uene mu jibha dingi athu avulu tundé ku muvu ua 1990.
O uhaxi ua kijimbu mu manhinga, u jibha athu avulu, bhenge-bhenge mu jixi mua kambe o jinzo ja ku saka.
Maji se a a mona ni lusolo, anga a a saka, a tena ku disanza ni ku sosolola o kufua.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Kitendelesu:']
['O kijimbuete kiki, phala ku longa ngó, ki kiene mu bhana milongi ia lungu ni sauidi.']
['O milongi íii, ka tokala ku i tumbula phala ku saka uhaxi, mba ku saka mauhaxi a mukuá.']
['Mu kifika, o ji komputadolo jene mu kuatekesa o athu kuijiia o ima ia lungu ni uhaxi, ki ji tena ku jimbulula kiambote o maka.']
['Sota kikuatekesu kia dotolo iê mba muthu ua mukuá uala ni uhete ua ku saka mauhaxi. Kana ku jimba o itendelesu ia dotolo mukonda dia milongi i ua tange mu kijimbuete kiki. Se ua mesena kikuatekesu, xinda ku muxinda ua 112, mba ndé mu inzo ia ku saka ia zukama.']
['Iala ni Kikutu ni Jinguvulu ja Jixi Jengi']
['O Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (o DMCA) i bhana ku athu ala ni ufolo ua ku soneka, o ima ia mona mu Internete, i bhukumukina o ufolo uâ ua ku soneka. ']
['Se eie u xikina ni kidi kioso kuila o milongi mba milongi i ua mu tanga mu kijimbuete kietu kia internete, mba mu ima ia mukuá, ia mu bhukumukina o itumu iê, eie (mba o muthu u ua mu tumina) u tena ku tu tumikisa mukanda ni ku tu bhinga phala ku katula o milongi mba milongi i ua mu tanga mba ku fidisa o muthu ku i tanga.']
['O ngolokela a tokala ku i tumikisa mu mukanda ni mu kijimbuete kia i-me-le (Tala o mbandu "Utuameni ua Ijimbuete") ].']
['O DMCA i bhinga kuila o njimbu iê ia lungu ni ku bhukumukina o itumu ia ku tokala, i kala ni milongi íii: (1) kijimbuluilu kia kikalakalu kia tokala ku kitumu kia ku tokala; (2) kijimbuluilu kia milongi ia ku tokala ni milongi i tua tokala ku sanga; (3) o ijimbuete iê, ni ijimbuete ia mutelembe uê; (4) ni izuelu i ua zuela kuila eie u xikina ni kidi kioso kuila o milongi ia ku tokala, ki i tokala ku ngana ia tokala, mba ku mukunji uê, mba ku kitumu kioso-kioso; ']
['(5) O kijimbuete kiê, ni kijimbuete kia ku tangela kuila o milongi iala mu kijimbuete kiki ia kidi, ni kuila eie uala ni kutena kua ku langa o ima ia ku tokala;']
['O kijimbuete kiki, ki tena ku kala ni kidimbu kiê, mba kijimbuete kia muthu ua mu tumina o ku ki jikula.']
['Se ku soneka o ima ioso íii, o ku tokuesa o maka mê kua-nda laleka.']
['Kuzuela ni Muthu']
['Tua ku dióndo, tu tumikise njimbu ni ibhuidisu mba jindunge.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['O ku']
['O BioMedLib i kalakala ni ji komputadolo phala ku bhanga ibhuidisu ni itambuijilu.']
['Tua mateka ni 35 a mazunda a madivulu a lungu ni sauidi mu internete, ni madivulu a mukuá a ubhe.']
['Tanga o mbandu "Referências" ni mbandu "Disclaimer".']
